- Active, not recruiting
NCT03798678: Phase 1 - CB-839 HCl + Carfilzomib and Dex - Refractory MM
Updated: May 26, 2022
CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
This phase I trial studies the best dose of CB-839 HCl when given together with carfilzomib and dexamethasone in treating patients with multiple myeloma that has come back or does not respond to previous treatment. CB-839 HCl and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Giving CB-839 HCl, carfilzomib, and dexamethasone may work better in treating patients with multiple myeloma.
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT03798678
Official Title: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination With Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
First Posted : January 10, 2019
Click here for details on ClinicalTrials.gov
Glutaminase Inhibitor CB-839 Hydrochloride - National Cancer Institute
Dexamethasone : National Cancer Institute